Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep885 | Pituitary and Neuroendocrinology | ECE2023

Crooke’s Cell Adenoma:Aggressive Corticotroph Adenoma

Ni Aung Nwe , Azad Fatima , Butt Nouman

Introduction: Crooke’s cell adenomas are nonneoplastic corticotropes with cytoplasmic accumulation of cytokeratin filaments in response to glucocorticoid excess. They are rare subtype of corticotrope adenomas presenting less than 1 % of pituitary adenomas.Case: 52 years old man attended Ophthalmology Clinic with 2 months history of right-sided reduced vision. He had a history of posterior polymorphous corneal dystrophy with a left corneal transplant...

ea0007p274 | Clinical case reports | BES2004

Crooke Cell Adenoma: case report of a rare but aggressive tumour

O'Shea L , Farrell M , Phillips J , Kinsley B , Firth R

Crooke Cell Adenoma (CCA) is a rare variant of ACTH-secreting corticotroph adenoma. Its importance derives from its aggressive behaviour, association with Cushings Disease and differentiation from metastatic carcinoma. A sixty-year old shopkeeper presented with a two-year history of generalised aches and pains, proximal muscle weakness, increased facial hair and easy bruising. She had also noticed an increased abdominal girth and facial rotundity. There was an eight-year histo...

ea0070ep354 | Pituitary and Neuroendocrinology | ECE2020

Crooke’s cell adenoma and cushing disease: A severe case report

Vasques Miguel , Matos Lurdes , Sagarribay Amets , Pontinha Carlos , Mafra Manuela , Cerqueira Luís , Agapito Ana

Introduction: Cushing’s disease (CD) is a potentially fatal disease caused by corticotrophic adenoma of the pituitary gland. Crooke Cell Adenomas (CCA) are a rare variant characterized by cytoplasmic ring deposits of cytokeratin filaments. They are usually aggressive macroadenomas with a higher rate of recurrence and malignancy.Clinical case: A 36 year old man, with 34 kg weight gain and uncontrolled hypertension for 4 years presented at the Emerge...

ea0050ep071 | Neuroendocrinology and Pituitary | SFEBES2017

Cushing’s disease caused by pituitary macroadenoma exhibiting Crooke’s hyaline changes and immunoreactivity for adrenocorticotrophic hormone and growth hormone

Novodvorsky Peter , Ince Paul G , Sinha Saurabh , Debono Miguel

Introduction: Cushing’s disease is usually caused by functional corticotroph microadenomas of the pituitary. Crooke’s cell adenomas are rare, representing approximately 2% of corticotroph adenomas and mostly present as aggressive macroadenomas. Pituitary adenomas showing immunoreactivity for both ACTH and GH are also very uncommon. We present two cases of Cushing’s disease caused by macroadenomas with Crooke’s cell cha...

ea0050ep071 | Neuroendocrinology and Pituitary | SFEBES2017

Cushing’s disease caused by pituitary macroadenoma exhibiting Crooke’s hyaline changes and immunoreactivity for adrenocorticotrophic hormone and growth hormone

Novodvorsky Peter , Ince Paul G , Sinha Saurabh , Debono Miguel

Introduction: Cushing’s disease is usually caused by functional corticotroph microadenomas of the pituitary. Crooke’s cell adenomas are rare, representing approximately 2% of corticotroph adenomas and mostly present as aggressive macroadenomas. Pituitary adenomas showing immunoreactivity for both ACTH and GH are also very uncommon. We present two cases of Cushing’s disease caused by macroadenomas with Crooke’s cell cha...

ea0035p225 | Clinical case reports Pituitary/Adrenal | ECE2014

Temozolomide-induced marked regression of invasive Crooke's cells corticotropinoma in patient with Cushing's disease

Kurowska Maria , Malicka Joanna , Zielinski Grzegorz , Tarach Jerzy S , Maksymowicz Maria , Denew Piotr

Introduction: Crooke’s cells are normal corticotrophs with cytoplasmic accumulation of cytokeratin filaments in response to glucocorticoids excess. Crooke’s cell corticotropinomas are the unique cause of Cushing’s disease. Nearly all of them are invasive macroadenomas, generally aggressive, refractory to conventional therapy, with high recurrence rate.Aim of the study was to present a case study of a patient with Cushing’s disease cau...

ea0090ep816 | Pituitary and Neuroendocrinology | ECE2023

A Rare Pituitary Pathology: Patient With Crooke Cell Corticotroph Adenoma

Yiğit Koroğlu Ekin , Aydin Cevdet , Keskin Caglar , Faruk Turkoğlu Omer , Gureşci Servet , Topaloglu Oya , Ersoy Reyhan , Cakir Bekir

However ACTH secreting adenomas are one of the most common functional pituitary tumors, subtypes such as Crooke cell corticotroph adenoma(CCCA) are relatively rare. We present here a patient with CCCA who had severe hypercortisolism mimicking ectopic ACTH syndrome. A 69 years old female patient admitted to emergency department after a fall. On cranial MRI,’a 3.5x2.5x3cm mass appearance with a sellar-suprasellar location, which is compressing the optic chiasm, expanding th...

ea0063p1105 | Pituitary and Neuroendocrinology 3 | ECE2019

Aggressive corticotroph adenoma

Stancu Cristina , Enculescu Augustina , Caragheorgheopol Andra , Badiu Corin

Aggressive pituitary tumors (APT) causing Cushing’s Disease are very rare, difficult to treat. The majority of Crooke’s corticotropinomas are macroadenomas, exhibiting rapid growth, resistance to conventional treatments, a high recurrence rate. To date, there is no fully effective method of treatment for these tumors. Pituitary carcinomas (PC) are defined by distant metastasis. PC is exceedingly rare, comprising only 0.1–0.2% of all pituitary neoplasms but APT m...

ea0049ep850 | Clinical case reports - Pituitary/Adrenal | ECE2017

Temozolomide alone or in combination with bevacizumab and capecitabine in the treatment of atypical pituitary adenomas – own experience

Kurowska Maria , Malicka Joanna , Tarach Jerzy

Introduction: Atypical pituitary adenomas are tumors refractory to conventional therapy and characterized by a tendency to rapid progression and high recurrence rate. The aim of the study was to summarize our experience in treatment of atypical pituitary adenomas with temozolomide (TMZ).Material: 5 patients (3F;2M) aged 44–58 (mean 52.4±5.4) years treated in 2013–2016. We analyzed the results, tolerance and side effects of TMZ.<p class...

ea0063p678 | Pituitary and Neuroendocrinology 2 | ECE2019

Case report of pituitary adenoma with subclinical Cushing’s disease

Tampouratzi Dimitra , Kalaitzidou Styliani , Papadakis Georgios , Karavasili Chrysi , Kotis Michalis , Sapera Ageliki , Aravantinou Ageliki , Roumpidaki Zoi , Dracopoulou Anna , Kaltzidou Victoria , Tertipi Athanasia

Background: Subclinical Cushing disease is defined by mild hypercortisolism that results from a corticotroph pituitary adenoma, without any typical sign of the disease. The patients often have coexisting metabolic diseases such as diabetes mellitus, and hypertension. Conversely, silent corticotroph adenomas demonstrate normal cortisol secretion, but positive immunochemistry for ACTH, most usually without ACTH hypersecretion, although they and can progress to clinical Cushing d...